Uterine Cervical Cancer is the most common cause of cancer, as well as the most common cause of death from cancer in women around the world. It was estimated that 528,000 cases of cervical cancer occurred, with 266,000 deaths in 2012 alone. This is about 8% of the total cases and total cancer deaths. About 70% of cervical cancers occur in developing countries. In low-income countries, it is the most common cause of cancer deaths. In developed countries, the widespread use of cervical screening programs has dramatically reduced rates of cervical cancers.
Cervical cancer is a cancer arising from the uterine cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. No symptoms are seen in earlier stages of disease process. Later symptoms may include abnormal vaginal bleeding, pelvic pain, or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.
According to studies, Human papillomavirus (HPV) infection appears to be involved in the development of more than 90% of cases of cervical cancers. Sametime, it is also true that most people who have had HPV infections, however, do not develop cervical cancer. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Cervical cancer typically develops from precancerous changes over 10 to 20 years. About 90% of cervical cancer cases are squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Diagnosis is typically by cervical screening followed by a biopsy. Medical imaging is also done to determine whether or not the cancer has spread.
The early stages of cervical cancer may be completely free of symptoms. Vaginal bleeding, contact bleeding (one most common form being bleeding after sexual intercourse), or (rarely) a vaginal mass may indicate the presence of malignancy. Also, moderate pain during sexual intercourse and vaginal discharge are symptoms of cervical cancer. In advanced disease, metastases may be present in the abdomen, lungs, or elsewhere.
Symptoms of advanced cervical cancer may include: loss of appetite, weight loss, fatigue, pelvic pain, back pain, leg pain, swollen legs, heavy vaginal bleeding, bone fractures, and/or (rarely) leakage of urine or feces from the vagina. Bleeding after douching or after a pelvic exam is a common symptom of cervical cancer
Infection with HPV is generally believed to be required for cervical cancer to occur. Genital warts, which are a form of benign tumor of epithelial cells, are also caused by various strains of HPV. However, these serotypes are usually not related to cervical cancer. It is common to have multiple strains at the same time, including those that can cause cervical cancer along with those that cause warts.
Cigarette smoking, both active and passive, increases the risk of cervical cancer. Among HPV-infected women, current and former smokers have roughly two to three times the incidence of invasive cancer. Passive smoking is also associated with increased risk, but to a lesser extent.
Long-term use of oral contraceptives is associated with increased risk of cervical cancer. Women who have used oral contraceptives for 5 to 9 years have about three times the incidence of invasive cancer, and those who used them for 10 years or longer have about four times the risk.
Having many pregnancies is associated with an increased risk of cervical cancer. Among HPV-infected women, those who have had seven or more full-term pregnancies have around four times the risk of cancer compared with women with no pregnancies, and two to three times the risk of women who have had one or two full-term pregnancies.
HPV vaccines have been developed to protect against between two and seven high-risk strains of this family of viruses and may prevent up to 90% of cervical cancers. As a risk of cancer still exists, guidelines recommend continuing regular Pap smears even after vaccinations. Other methods of prevention include: having few or no sexual partners and the use of condoms. Cervical cancer screening using the Pap smear or acetic acid can identify precancerous changes which when treated can prevent the development of cancer. Modern treatment of cervical cancer may consist of some combination of surgery, chemotherapy, and radiotherapy. Five year survival rates in the United States by these treatment protocols are 68%. Outcomes, however, depend very much on how early the cancer is detected.
Preventive vaccines are currently developed to protect against the two HPV types (16 and 18) that cause about 70% of cervical cancers worldwide. Vaccines that protect against more of the types common in cancers are expected to prevent more cancers. For instance, a vaccine against the seven types most common in cervical cancers (16, 18, 45, 31, 33, 52, 58) is estimated to prevent 87% of cervical cancers worldwide.
HPV types 16, 18 and 45 contribute to 94% of cervical adenocarcinoma (cancers originating in the glandular cells of the cervix). While most cervical cancer arises in the squamous cells, adenocarcinomas make up a sizable minority of cancers. Further, Pap smears are not as effective at detecting adenocarcinomas, so where Pap screening programs are in place, a larger proportion of the remaining cancers are adenocarcinomas.
HPV vaccine ‘Gardasil’ contains inactive L1 proteins from four different HPV strains: 6, 11, 16, and 18. Together, these HPV types 16 and 18 currently cause about 70 percent of all cervical cancer, and about 90 percent of all cases of genital warts. HPV types 6 and 11 are much less likely to cause cancer, but do cause genital warts.
Only a small percentage of women with cervical cancer in the developing world get diagnosed and treated in early stages. Most cases are identified only after reaching an incurable stage. HPV vaccinations may be effective to certain extent, but its cost is very high, making mass vaccination programs unaffordable to poor countries.
Currently the HPV vaccine is not recommended for pregnant women. There have been reports of death in females after receiving the vaccine, even though such deaths were not linked to the vaccine beyond doubts. Additionally, there have been rare reports of blood clots forming in the heart, lungs and legs after getting vaccinated. There have been 22,000 Vaccine Adverse Event Reporting System (VAERS) reports following the HPV vaccination in US alone, even though ninety-two percent were reports of events considered to be non-serious (e.g., fainting, pain and swelling at the injection site (arm), headache, nausea and fever). But 9 percent were considered to be serious (death, permanent disability, life-threatening illness and hospitalization).
The long-term effects of the vaccine on fertility are not known, but no effects are anticipated. Even though FDA has classified the HPV vaccine as a pregnancy Category B, meaning there is no apparent harm on the fetus in animal studies, and HPV vaccines have not been causally related with adverse pregnancy outcomes or adverse effects on the fetus, data on vaccination during pregnancy is very limited. It has been advised that vaccination during the pregnancy term should be delayed until more information is available. If a woman is found to be pregnant during the three dose series of vaccination, the series will be postponed until pregnancy has been completed.
Risk of long term adverse effects of HPV vaccines also cannot be ignored. Antibodies generated in the body in response to vaccinations may remain as ‘miasms’ for long periods, causing ‘off-target’ molecular inhibitions that may produce diverse kinds of chronic disease dispositions. In this circumstance, we have to think about more scientific, safe and cost-effective alternative ways for preventing and treating cervical cancers in the society.
It is very important to note that currently available HPV vaccines do not treat existing HPV infection or cervical cancer. HPV vaccines are used only to prevent HPV infection and therefore cervical cancer. They are recommended for women who are 9 to 25 years old who have not been exposed to HPV. However, since it is very unlikely that a woman will have already contracted all four viruses, since HPV is primarily sexually transmitted.
Here comes the relevance of MIT approach to cervical cancers, considering the risks and limitations of HPV vaccines. Molecular Imprints of viral proteins of multiple strains of Human Papilloma Virus could be produced and used as prophylactic as well as therapeutic agents against this disease.
The HPV vaccines are based on hollow virus-like particles (VLPs) assembled from recombinant HPV coat proteins. The virus possesses circular double stranded DNA and a viral shell that is composed of 72 capsomeres. Every subunit of the virus is composed of two proteins molecules, L1 and L2. The reason why this virus has the capability to affect the skin and the mucous layers is due to its structure. The primary structures expressed in these areas are E1 and E2, these proteins are responsible for the replication of the virus. E1 is a highly conserved protein in the virus, E1 is in charge of the production of viral copies is also involved in every step of replication process. The second component of this process is E2 ensures that non-specific interaction occur while interacting with E1. As a result of these proteins working together is assures that numerous amounts of copies are made within the host cell. The structure of the virus is critical because this influence the infection affinity of the virus. Knowing the structure of the virus allowed for the development of HPV vaccines.
Molecular Imprints could be prepared in a ‘water-alcohol’ matrix from these ‘hpv coat proteins’, especially L1 and L2 proteins which constitute every subunit of the HPV virus, by the process of homeopathic potentization. These molecular imprints will have conformations exactly opposite to the conformations of functional groups of L1 and L2 proteins. Due to this complementary conformations, these molecular imprints can act as ‘artificial binding sites’ for viral proteins, thereby preventing their interactions with biological molecules in human body. By this bio-molecular mechanism, HPV infection is prevented, and disease processes in already infected persons reversed.
According to MIT perspective, it is obvious from the above discussions that ‘L1 proteins’ extracted from four different HPV strains (6, 11, 16, and 18) and potentized above 12c will be the ideal homeopathic drug for prevention and treatment of UTERINE CERVICAL CANCERS caused by Human Papilloma Viruses.
Of course, MEDORRHINUM 12C or 30C will play a major role in MIT protocol for cervical cancer treatment, since this homeopathic nosode is prepared from disease products containing a combination of infectious agents of gonorrhea as well as ‘figwart disease’ or human papilloma virus disease. MEDORRHINUM in potentized form will most probably contain molecular imprints of ‘hpv coat proteins’. CARCINOCIN 30 also should be included, as it will contain molecular imprints capable of deactivating various chemical molecules synthesized by cancer cells
Homeopathic constitutional SIMILIMUM selected on the basis of mental symptoms and physical generals also should be included in this treatment protocol in potencies above 12C for a complete cure.